Scott Gottlieb prepares to leave the FDA after accomplishing much.

Research and development tax reliefs are available for businesses in many countries, but some companies are not taking advantage.

A recently published report shows how the European Commission has protected patients against anticompetitive practices over the last decade.

Are healthcare systems and manufacturers ready to embrace evidence-based pricing to lessen the impact of upfront costs of advanced therapies?

Angela Osborne has created her own space in the industry and is helping the cell and gene therapy industry bloom.

EU will allow companies to carry out QC testing in the UK after a "no deal" Brexit, at least under certain conditions and for a limited time.

The potential market for complex generics is substantial, but navigating the FDA’s guidance for proving “sameness” is a real minefield...

Valor® Glass is a revolutionary, new aluminosilicate glass composition, developed specifically for pharmaceutical use to eliminate delamination.

It's time to take action against TB.

If cell and gene therapy products are to successfully reach patients, then the industry will need more facilities capable of manufacturing them.